| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 77.14M | 75.51M | 83.14M | 52.52M | 113.97M | 99.48M |
| Gross Profit | 22.11M | 20.74M | 14.68M | 10.83M | 41.73M | 38.58M |
| EBITDA | -65.72M | -74.79M | -4.51M | -61.82M | -29.28M | -25.02M |
| Net Income | -40.38M | -47.43M | -7.29M | -67.91M | -40.61M | -78.33M |
Balance Sheet | ||||||
| Total Assets | 2.95B | 3.20B | 1.83B | 1.98B | 2.77B | 2.84B |
| Cash, Cash Equivalents and Short-Term Investments | 84.52M | 152.56M | 263.55M | 164.96M | 318.68M | 150.76M |
| Total Debt | 110.93M | 90.49M | 115.50M | 141.74M | 178.95M | 497.97M |
| Total Liabilities | 454.60M | 474.25M | 334.40M | 362.69M | 545.67M | 904.76M |
| Stockholders Equity | 2.49B | 2.73B | 1.49B | 1.62B | 2.22B | 1.94B |
Cash Flow | ||||||
| Free Cash Flow | -86.81M | -94.51M | -52.68M | -92.82M | 82.82M | -10.62M |
| Operating Cash Flow | -71.22M | -80.87M | -43.59M | -77.91M | 105.22M | 3.40M |
| Investing Cash Flow | 167.01M | 162.66M | 43.10M | -104.25M | 369.21M | -64.92M |
| Financing Cash Flow | 4.12M | -21.65M | -22.38M | -23.79M | -325.97M | -42.38M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$756.00M | 1.57 | 11.13% | ― | 13.88% | 1.52% | |
68 Neutral | HK$1.37B | 11.39 | 3.91% | 3.60% | 20.53% | 28.42% | |
66 Neutral | HK$817.07M | 3.14 | 8.32% | 4.69% | 8.09% | 30.76% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
52 Neutral | HK$732.93M | -2.19 | -89.45% | ― | 12.16% | -16700.00% | |
47 Neutral | HK$769.62M | -18.90 | -1.99% | ― | -5.59% | -1071.43% | |
41 Neutral | HK$483.26M | -1.90 | -98.45% | ― | -32.75% | 38.59% |
KuangChi Science Limited has announced the sale of 3,893,724 KCT shares on the Shenzhen Stock Exchange, generating net proceeds of RMB186.0 million. This transaction, classified as a discloseable transaction under the Listing Rules, is expected to result in a gain of RMB30.3 million for the company, enhancing its financial position and providing funds for refinancing and general working capital.
KuangChi Science Limited, a company incorporated in Bermuda, announced the results of its Special General Meeting held on December 1, 2025. During the meeting, shareholders approved a special resolution to change the company’s English name to ‘Genesis Scale Holdings Limited’ and adopt a new Chinese name. This change reflects a strategic rebranding effort, potentially signaling a shift in market focus or operational strategy.
KuangChi Science Limited has announced a special general meeting to consider changing its name to Genesis Scale Holdings Limited, pending approval from the Registrar of Companies in Bermuda. Additionally, the company seeks to adopt a new share option scheme, subject to the approval of the Hong Kong Stock Exchange, which aims to enhance shareholder value and provide incentives for eligible participants.
KuangChi Science Limited has proposed to change its English name to Genesis Scale Holdings Limited and adopt a new Chinese name. This change aims to provide a fresh corporate image that supports future business development. The name change is subject to shareholder approval and regulatory consent in Bermuda. The change will not affect shareholder rights, and existing share certificates will remain valid.
KuangChi Science Limited has announced the expiration of its 2012 Share Option Scheme, which was adopted on July 31, 2012, and expired on July 30, 2022. In response, the company proposes to adopt a New Share Option Scheme to provide incentives for participants contributing to the company’s growth. This proposal is subject to shareholder approval and the necessary permissions from the Stock Exchange. The new scheme aims to continue motivating and rewarding participants, aligning with the company’s strategic goals.
KuangChi Science Limited has announced a change in its executive directors, with Dr. Liu Ruopeng, Dr. Luan Lin, and Dr. Ji Chunlin resigning to focus on other business commitments. The company has appointed Dr. Liu Weiwen, the current CEO, and Mr. Lin Ge as new executive directors, effective from September 10, 2025. This leadership change is part of the company’s ongoing management restructuring, which may impact its strategic direction and operational focus.
KuangChi Science Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The company has also detailed the membership of its board committees, which are the Audit Committee, Nomination Committee, and Remuneration Committee. This announcement provides clarity on the leadership structure and governance of KuangChi Science Limited, potentially impacting its strategic direction and stakeholder engagement.